Telangana, India

Vivek Dubey

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vivek Dubey: Innovator in Pharmaceutical Formulations

Introduction

Vivek Dubey is a notable inventor based in Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in developing formulations that address serious respiratory conditions. His work is characterized by a commitment to improving patient outcomes through innovative solutions.

Latest Patents

Vivek Dubey holds a patent for the formulation of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide. This patent describes compounds and pharmaceutical compositions that are useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis, or asthma. The formulations aim to provide a therapeutically effective amount of the compound to subjects in need, showcasing his dedication to addressing critical health issues.

Career Highlights

Vivek Dubey is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to leverage his expertise in pharmaceutical research and development. His innovative approach has contributed to the advancement of therapeutic options available for patients suffering from chronic respiratory diseases.

Collaborations

Throughout his career, Vivek has collaborated with talented professionals in the field. Notable coworkers include Rohit Lowalekar and Paulo G Santos, who have worked alongside him in various projects aimed at enhancing pharmaceutical formulations.

Conclusion

Vivek Dubey's contributions to pharmaceutical innovations reflect his commitment to improving healthcare solutions. His patent for a novel formulation demonstrates his role as a key player in the fight against respiratory diseases. His work continues to inspire advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…